ClinicalTrials.gg
RecruitingNCT05329285STICHUpdated Oct 13, 2026

CABG or PCI in Patients With Ischemic Cardiomyopathy

An interventional study of Percutaneous Coronary Intervention (PCI) in Coronary Artery Disease, sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Updated Oct 13, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Coronary Artery Disease with a site in Sweden — 14 open to participants now, 24 under way, 3 of them phase 3. Coronary Artery Disease · Sweden.

Planned enrollment
37th of 71
470 · median 500
Started
2022
with 3 others
No phase
39 of 92
7 open now
Primary completion
2028-12
later than 15 of 23 live
Registered
76th of 92
by date
Lead sponsor
4 of 92
Vastra Gotaland Region

Among the 92 studies in Coronary Artery Disease with a site in Sweden, this one is the 37th largest by planned enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2022, is one of 39 with no phase, reaches primary completion later than 15 of the 23 other live ones, and was the 76th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

14 of the 92 studies in Coronary Artery Disease with a site in Sweden are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Coronary Artery Disease with a site in Sweden, or all of them as a file.
02

Study summary

The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \<40%) and multi-vessel coronary artery disease.

Read the detailed description

Short background/ Rationale/Aim:

CABG has been shown to prolong survival in patients with reduced left ventricular (LV) function and multi-vessel coronary artery disease and "CABG is recommended as the first revascularization strategy choice in patients with multi-vessel disease and acceptable surgical risk". However, a major concern with CABG is the early risk of complications, including death and stroke. Although PCI has lower rates of peri-procedural complications than CABG in patients without heart failure (HF), this has not been confirmed in patients with HF. The lack of contemporary data comparing CABG and PCI in HF leaves clinicians with no guidance as to which option to choose, and a robust trial is therefore necessary. The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \< 40%) and multi-vessel coronary artery disease.

Study objective:

To test whether PCI is non-inferior to CABG for revascularization of patients with ischemic heart failure.

Study design:

Multicentre, open-label, randomized controlled trial

Study population:

Patients with ischemic cardiomyopathy and reduced ejection fraction.

Number of subjects:

470 subjects

Investigational treatment:

PCI

Treatment in control group:

CABG

Study endpoints:

Primary endpoint (variable):

The occurrence of the composite of death, stroke, non-procedural myocardial infarction or heart failure hospitalization at 3 years.

Key secondary endpoint The hierarchical occurrence (in descending order of importance) at 3-year follow-up of time to death, time to stroke, time to non-procedural myocardial infarction, number of heart failure hospitalizations and 1-year Kansas City Cardiomyopathy Questionnaire (KCCQ) score; evaluated using the win ratio approach.

Secondary safety endpoints

In-hospital occurrence of the following:

  1. Death
  2. Stroke
  3. Non-procedural myocardial infarction
  4. The occurrence of in-hospital BARC ≥3 bleeding

    Time to the occurrence of the following:

  5. Mediastinitis
  6. Pericardial tamponade Other secondary endpoints

1. Time to the occurrence of the following: A. Death, stroke or non-procedural myocardial infarction B. Death or heart failure hospitalization C. Heart failure hospitalization D. Coronary revascularization E. Death or myocardial infarction F. Death or stroke 2. Total number of days in-hospital during index hospitalization 3. Total number of days in intensive care unit during index hospitalization 4. Quality of life at 30 days and 365 days.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • PCI
  • CABG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Symptomatic HF defined as HF class II-IV within 1 month of enrolment
  3. ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF
  4. Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (> 6 months) coronary angiogram);
  5. Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle
  6. Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization
  7. Written obtained

Exclusion criteria

Exclusion Criteria:

  1. Previous randomization in the study
  2. Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization
  3. Recent (\<1 month) type 1 myocardial infarction
  4. Recent PCI (\<3 months)
  5. Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement
  6. Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy
  7. Expected survival less than 3 years due to non-cardiac illness
  8. Circumstances likely to lead to poor treatment compliance
  9. Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems
  10. Pregnancy or woman of who is not sterilized or using a medically accepted form of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    Percutaneous Coronary Intervention (PCI)

    Patients will be revascularized by PCI

    Procedure: Percutaneous Coronary Intervention (PCI)

  • No intervention
    Coronary artery bypass grafting (CABG)

    Patients will be revascularized by CABG

Interventions

  • ProcedurePercutaneous Coronary Intervention (PCI)

    Alternative treatment

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac event

    The occurrence of the composite of death, stroke, non-procedural myocardial infarction or heart failure hospitalization

    Time frame: 3 years

Secondary outcomes

  1. The occurrence of death

    Time to death

    Time frame: 3 years

  2. The occurrence of stroke

    Time to stroke

    Time frame: 3 year

  3. The occurrence of non-procedural myocardial infarction,

    Time to non-procedural myocardial infarction,

    Time frame: 3 year

  4. The occurrence of heart failure hospitalizations

    Number of heart failure hospitalizations

    Time frame: 3 year

  5. Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    Kansas City Cardiomyopathy Questionnaire score; evaluated using the win ratio approach. High score mean a better outcome

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Kardiologen
    Gothenburg, 41345, Sweden
    Recruiting
08

References and documents

Publications

  • Thuan PQ, Chuong PTV, Nam NH, Dinh NH. Coronary Artery Bypass Surgery: Evidence-Based Practice. Cardiol Rev. 2025 Jul-Aug 01;33(4):344-351. doi: 10.1097/CRD.0000000000000621. Epub 2023 Dec 19. PubMed 38112423 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2028, 75 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 75 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Apr 15, 2022
StartActual
Sep 14, 2022
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2052
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Kardiologen · Gothenburg, Sweden
Show 1 removed
  • Kardiologen · Göteborg, Sweden
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38112423 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38112423 ↗
    1 site added, 1 site removed
    Show site
    • Kardiologen · Gothenburg, Sweden
    Show 1 removed
    • Kardiologen · Göteborg, Sweden
    + 4 other changes: index terms, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05329285
Collaborators
Region Örebro County, Karolinska University Hospital, University Hospital, Umeå
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Sep 14, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2052 (estimated)
Last update
Oct 13, 2026

Study contacts

Björn Redfors, MD, PhD
Contact
Bjoern.Redfors@wlab.gu.se
+46313427543
Elmir Omerovic, MD, PhD
Contact
elmir@wlab.gu.se
+46 31 3421000
Björn Redfors, Professor
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion